BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 32962091)

  • 1. FGFR Fusions in Cancer: From Diagnostic Approaches to Therapeutic Intervention.
    De Luca A; Esposito Abate R; Rachiglio AM; Maiello MR; Esposito C; Schettino C; Izzo F; Nasti G; Normanno N
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32962091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implications of Fibroblast Growth Factors (FGFs) in Cancer: From Prognostic to Therapeutic Applications.
    Dianat-Moghadam H; Teimoori-Toolabi L
    Curr Drug Targets; 2019; 20(8):852-870. PubMed ID: 30648505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors.
    Hierro C; Rodon J; Tabernero J
    Semin Oncol; 2015 Dec; 42(6):801-19. PubMed ID: 26615127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of targetable FGFR gene fusions in diverse cancers.
    Wu YM; Su F; Kalyana-Sundaram S; Khazanov N; Ateeq B; Cao X; Lonigro RJ; Vats P; Wang R; Lin SF; Cheng AJ; Kunju LP; Siddiqui J; Tomlins SA; Wyngaard P; Sadis S; Roychowdhury S; Hussain MH; Feng FY; Zalupski MM; Talpaz M; Pienta KJ; Rhodes DR; Robinson DR; Chinnaiyan AM
    Cancer Discov; 2013 Jun; 3(6):636-47. PubMed ID: 23558953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder.
    Roskoski R
    Pharmacol Res; 2020 Jan; 151():104567. PubMed ID: 31770593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FGFR a promising druggable target in cancer: Molecular biology and new drugs.
    Porta R; Borea R; Coelho A; Khan S; Araújo A; Reclusa P; Franchina T; Van Der Steen N; Van Dam P; Ferri J; Sirera R; Naing A; Hong D; Rolfo C
    Crit Rev Oncol Hematol; 2017 May; 113():256-267. PubMed ID: 28427515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances and challenges in targeting FGFR signalling in cancer.
    Babina IS; Turner NC
    Nat Rev Cancer; 2017 May; 17(5):318-332. PubMed ID: 28303906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent developments and advances of FGFR as a potential target in cancer.
    Xue WJ; Li MT; Chen L; Sun LP; Li YY
    Future Med Chem; 2018 Sep; 10(17):2109-2126. PubMed ID: 30066580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting FGFR Signaling in Cancer.
    Touat M; Ileana E; Postel-Vinay S; André F; Soria JC
    Clin Cancer Res; 2015 Jun; 21(12):2684-94. PubMed ID: 26078430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibroblast growth factor receptor signaling as therapeutic targets in gastric cancer.
    Yashiro M; Matsuoka T
    World J Gastroenterol; 2016 Feb; 22(8):2415-23. PubMed ID: 26937130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibroblast growth factor receptor fusions in cancer: opportunities and challenges.
    Chen L; Zhang Y; Yin L; Cai B; Huang P; Li X; Liang G
    J Exp Clin Cancer Res; 2021 Nov; 40(1):345. PubMed ID: 34732230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of Known and Novel FGFR Fusions in Non-Small Cell Lung Cancer by Comprehensive Genomic Profiling.
    Qin A; Johnson A; Ross JS; Miller VA; Ali SM; Schrock AB; Gadgeel SM
    J Thorac Oncol; 2019 Jan; 14(1):54-62. PubMed ID: 30267839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FGFR-targeted therapeutics for the treatment of breast cancer.
    De Luca A; Frezzetti D; Gallo M; Normanno N
    Expert Opin Investig Drugs; 2017 Mar; 26(3):303-311. PubMed ID: 28121208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting mutant fibroblast growth factor receptors in cancer.
    Greulich H; Pollock PM
    Trends Mol Med; 2011 May; 17(5):283-92. PubMed ID: 21367659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy.
    Biello F; Burrafato G; Rijavec E; Genova C; Barletta G; Truini A; Coco S; Bello MG; Alama A; Boccardo F; Grossi F
    Anticancer Agents Med Chem; 2016; 16(9):1142-54. PubMed ID: 26845137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FGFR-TKI resistance in cancer: current status and perspectives.
    Yue S; Li Y; Chen X; Wang J; Li M; Chen Y; Wu D
    J Hematol Oncol; 2021 Feb; 14(1):23. PubMed ID: 33568192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting FGFR in bladder cancer: ready for clinical practice?
    De Keukeleire S; De Maeseneer D; Jacobs C; Rottey S
    Acta Clin Belg; 2020 Feb; 75(1):49-56. PubMed ID: 31671027
    [No Abstract]   [Full Text] [Related]  

  • 18. Future applications of FGF/FGFR inhibitors in cancer.
    Ghedini GC; Ronca R; Presta M; Giacomini A
    Expert Rev Anticancer Ther; 2018 Sep; 18(9):861-872. PubMed ID: 29936878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing.
    Helsten T; Elkin S; Arthur E; Tomson BN; Carter J; Kurzrock R
    Clin Cancer Res; 2016 Jan; 22(1):259-67. PubMed ID: 26373574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical complexity of utilizing FGFR inhibitors in cancer therapeutics.
    Chandana SR; Babiker HM; Mahadevan D
    Expert Opin Investig Drugs; 2020 Dec; 29(12):1413-1429. PubMed ID: 33074030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.